GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (SHSE:688185) » Definitions » Return-on-Tangible-Asset

CanSino Biologics (SHSE:688185) Return-on-Tangible-Asset : -7.79% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is CanSino Biologics Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. CanSino Biologics's annualized Net Income for the quarter that ended in Mar. 2024 was ¥-680.4 Mil. CanSino Biologics's average total tangible assets for the quarter that ended in Mar. 2024 was ¥8,733.2 Mil. Therefore, CanSino Biologics's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -7.79%.

The historical rank and industry rank for CanSino Biologics's Return-on-Tangible-Asset or its related term are showing as below:

SHSE:688185' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -17.22   Med: -12.08   Max: 21.11
Current: -16.61

During the past 8 years, CanSino Biologics's highest Return-on-Tangible-Asset was 21.11%. The lowest was -17.22%. And the median was -12.08%.

SHSE:688185's Return-on-Tangible-Asset is ranked worse than
73.78% of 1083 companies
in the Drug Manufacturers industry
Industry Median: 1.76 vs SHSE:688185: -16.61

CanSino Biologics Return-on-Tangible-Asset Historical Data

The historical data trend for CanSino Biologics's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics Return-on-Tangible-Asset Chart

CanSino Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial -12.68 -9.44 20.86 -7.95 -14.59

CanSino Biologics Quarterly Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.98 -28.79 -6.01 -21.55 -7.79

Competitive Comparison of CanSino Biologics's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CanSino Biologics's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where CanSino Biologics's Return-on-Tangible-Asset falls into.



CanSino Biologics Return-on-Tangible-Asset Calculation

CanSino Biologics's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-1482.732/( (11210.221+9113.122)/ 2 )
=-1482.732/10161.6715
=-14.59 %

CanSino Biologics's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-680.384/( (9113.122+8353.267)/ 2 )
=-680.384/8733.1945
=-7.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


CanSino Biologics  (SHSE:688185) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


CanSino Biologics Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


CanSino Biologics (SHSE:688185) Business Description

Traded in Other Exchanges
Address
185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing and commercialization of vaccine products for human use. These include products such as pneumococcal polysaccharide and conjugate vaccines as well as a DTcP-based combo and other items. At the same time, the group is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine. Geographically, the activities are carried out through China.

CanSino Biologics (SHSE:688185) Headlines

No Headlines